Security Snapshot

Oruka Therapeutics, Inc. - COMMON STOCK (ORKA) Institutional Ownership

CUSIP: 687604108

13F Institutional Holders and Ownership History from Q3 2024 to Q3 2026

13F reference period

Q3 2026

Institutions Reporting

194

Shares (Excl. Options)

55.85MFull value: 55,853,607 · shares · 30 Sep 2026

Price

$83.29

The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0.01%
Share change
+4,367,241
Value change
+$355,446,056
Number of holders
194
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
66,547,970
SEC-reported price per share
$95.81
Insider filing price
$95.81
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • ORKA - Oruka Therapeutics, Inc. - COMMON STOCK is tracked under CUSIP 687604108.
  • 194 institutions reported positions in Q3 2026.
  • 8 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 255 to 194 between Q2 2026 and Q3 2026.
  • SEC-reported value moved from
    $7.05BFull value: $7,051,100,780 · USD · 30 Jun 2026
    to
    $4.69BFull value: $4,688,529,199 · USD · 30 Sep 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 194 institutions filings for Q3 2026.

Open SEC evidence

Security key

687604108

13F reference period

Q3 2026

13F holders

194

13D/G owners

8

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
8
Security
ORKA
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Fairmount Funds Management LLC 20% -2.4% $997,807,627 +$62,159,599 14,572,917 +6.6% Harwin Peter Evan 01 Jul 2026
Venrock Healthcare Capital Partners III, L.P. 7.4% -25% $384,606,749 -$29,765,095 4,556,952 -7.2% Venrock Healthcare Capital Partners III, L.P. 30 Jun 2026
T. Rowe Price Investment Management, Inc. 6.6% $365,823,506 4,392,166 T. Rowe Price Investment Management, Inc. 30 Sep 2026
Capital World Investors 5.6% $287,098,332 3,401,639 Capital World Investors 30 Jun 2026
BlackRock, Inc. 6.6% +42% $96,248,890 +$29,642,149 3,175,483 +45% BlackRock, Inc. 31 Dec 2025
RTW INVESTMENTS, LP 4.7% -10% $261,449,809 3,139,030 0% RTW Investments, LP 30 Sep 2026
Deep Track Capital, LP 4.5% -12% $65,515,368 +$8,023,966 2,161,510 +14% Deep Track Capital, LP 31 Dec 2025
VIKING GLOBAL INVESTORS LP 2.5% -56% $126,893,543 -$98,175,093 1,503,478 -44% VIKING GLOBAL INVESTORS LP 30 Jun 2026
As of 30 Sep 2026, 194 institutional investors reported holding
55.85MFull value: 55,853,607 · shares · 30 Sep 2026
shares of Oruka Therapeutics, Inc. - COMMON STOCK (ORKA). This represents 84% of the company’s total
66.55MFull value: 66,547,970 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
67%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
T. Rowe Price Investment Management, Inc. 6.6% 4,392,166 0.26% $365,824,000
Venrock Adviser, LLC 6.2% 4,148,428 17% $345,522,568
Fairmount Funds Management LLC 5.6% 3,705,262 19% $308,611,272
Capital World Investors 5.2% 3,429,066 0.03% $285,606,907
RTW INVESTMENTS, LP 4.7% 3,139,030 2.6% $261,449,809
STATE STREET CORP 4.2% 2,817,132 0.01% $234,617,269
VANGUARD CAPITAL MANAGEMENT LLC 4% 2,644,280 0% $220,242,081
Paradigm Biocapital Advisors LP 3.7% 2,493,507 4.1% $207,684,198
Janus Henderson Group Ltd. 2.8% 1,873,153 0.07% $155,957,838
Bellevue Group AG 2.5% 1,641,059 2.8% $136,683,804
VANGUARD PORTFOLIO MANAGEMENT LLC 2.4% 1,592,427 0.01% $132,633,245
RA CAPITAL MANAGEMENT, L.P. 2.3% 1,554,597 1.3% $129,482,384
GEODE CAPITAL MANAGEMENT, LLC 2.3% 1,545,458 0.01% $128,746,470
Polar Capital Holdings Plc 1.8% 1,224,841 0.29% $102,017,007
PERCEPTIVE ADVISORS LLC 1.6% 1,072,363 1.7% $89,317,114
Deep Track Capital, LP 1.6% 1,069,774 1.5% $89,101,476
Remedium Capital Partners, LLC 1.4% 954,150 29% $79,471,154
WESTFIELD CAPITAL MANAGEMENT CO LP 1.2% 829,749 0.23% $69,109,794
Avidity Partners Management LP 1.2% 785,424 15% $65,417,965
SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC 1.1% 723,922 2% $60,295,463
Aberdeen Group plc 0.95% 632,408 0.07% $52,673,262
Affinity Asset Advisors, LLC 0.9% 600,000 2.8% $49,974,000
GOLDMAN SACHS GROUP INC 0.87% 582,289 0.01% $48,498,851
VANGUARD FIDUCIARY TRUST CO 0.61% 403,555 0.01% $33,612,096
Pictet Asset Management Holding SA 0.6% 401,928 0.03% $33,475,789

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
9
Headline period
Q3 2026
Rows shown
1-9 of 9
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 55,853,607 $4,688,529,199 +$355,446,056 $83.29 194
2026 Q2 74,139,131 $7,051,100,780 +$1,979,836,886 $95.17 255
2026 Q1 52,018,172 $2,550,553,925 +$46,411,060 $49.05 183
2025 Q4 52,853,967 $1,602,044,506 +$170,793,609 $30.31 144
2025 Q3 45,557,412 $875,823,009 +$220,884,566 $19.23 104
2025 Q2 34,429,035 $385,950,468 +$30,431,109 $11.21 81
2025 Q1 31,776,517 $326,087,518 -$21,453,560 $10.26 70
2024 Q4 31,038,311 $606,624,310 +$125,781,752 $19.39 66
2024 Q3 24,559,501 $604,174,991 +$603,646,384 $24.51 41
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .